Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Study Identifier
RAP-MD-31
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact

Study Details

Medical Condition
  • Depression
  • Study Drug
  • Rapastinel
  • Vortioxetine
  • Placebo
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18 - 75 Years

    Protocol Summary

    The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to 10 mg of Vortixetine and placebo in participants with major depressive disorder (MDD).

    Study Locations

    No locations found.